Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.36 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | GRM8 | O00222 | 2/20 | 0.37 |
| ▸ | GRM6 | O15303 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19668636 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1GRM4CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL19668637 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1GRM4CYP1A2CYP2C19 | |
| SCHEMBL16967377 | 0.98 | SLC1A2 (0.43) | SLC1A2SLC1A1GRM4CYP1A2CYP2C19 | |
| SCHEMBL16967379 | 0.98 | SLC1A2 (0.43) | SLC1A2SLC1A1GRM4CYP1A2CYP2C19 | |
| SCHEMBL31472262 | 0.98 | SLC1A2 (0.43) | SLC1A2SLC1A1GRM4CYP1A2CYP2C19 | |
| SCHEMBL16967380 | 0.98 | SLC1A2 (0.43) | SLC1A2SLC1A1GRM4CYP1A2CYP2C19 | |
| SCHEMBL28204662 | 0.96 | SLC1A2 (0.42) | SLC1A2SLC1A1GRM4CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL30038057 | 0.94 | SLC1A2 (0.43) | SLC1A2SLC1A1GRM4CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL18298279 | 0.94 | SLC1A2 (0.43) | SLC1A2SLC1A1GRM4CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL2182021 | 0.94 | SLC1A2 (0.43) | SLC1A2SLC1A1GRM4CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12630808-B2 | Modified archaeal family b polymerases | Singular Genomics Systems, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4677087-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | Glaukos Corporation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250381270-A1 | ISOLATING ACTIVE T-CELL CARS FROM BULK TRANSDUCED HUMAN T-CELLS | UNIV CALIFORNIA (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | ENLAZA THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | INFLAMMX THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12454683-B2 | Modified archaeal family B polymerases | Singular Genomics Systems, Inc. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
| WO-2019204768-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-24 | — | — | WO | disclosed |
| US-10420843-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2019-09-24 | — | — | US | disclosed |
| WO-2019173760-A1 | BIOREACTIVE COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-12 | — | — | WO | disclosed |
| EP-3454907-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION | Thetis Pharmaceuticals LLC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10130719-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180200375-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | THETIS PHARMACEUTICALS LLC (US) | 2018-07-19 | — | — | US | disclosed |
| WO-2018097999-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20180110751-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | THETIS PHARMACEUTICALS LLC | 2018-04-26 | — | — | US | disclosed |
| WO-2017210604-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION | THETIS PHARMACEUTICALS LLC (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420843-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | PTGER1, PTGER4, PTGER2 | HSD11B1 345/4885SLC6A4 3462/4885SLC1A2 4193/4885 |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | NLRP3, GJA1, PYCARD | HSD11B1 3334/4885SLC6A4 2759/4885SLC1A2 1607/4885 |
| US-12630808-B2 | Modified archaeal family b polymerases | SSU72, POLB, POLQ | HSD11B1 3491/4885SLC6A4 3461/4885SLC1A2 1046/4885 |
| US-20180200375-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | ALOX15B, LTB4R2, ALOX5 | HSD11B1 148/4885SLC6A4 2512/4885SLC1A2 4047/4885 |
| US-20250381270-A1 | ISOLATING ACTIVE T-CELL CARS FROM BULK TRANSDUCED HUMAN T-CELLS | PBK, CD4, ICOS | HSD11B1 3404/4885SLC6A4 4882/4885SLC1A2 4629/4885 |
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | FCGR3B, FCGR2A, CD22 | HSD11B1 4656/4885SLC6A4 4439/4885SLC1A2 1096/4885 |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | POLB, POLM, POLRMT | HSD11B1 2442/4885SLC6A4 1934/4885SLC1A2 1127/4885 |
| US-20180110751-A1 | COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS | ALOX15B, LTB4R2, ALOX5 | HSD11B1 148/4885SLC6A4 2512/4885SLC1A2 4047/4885 |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | RNASE1, ADAM8, CTRL | HSD11B1 3034/4885SLC6A4 4804/4885SLC1A2 4864/4885 |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | DNMT3A, POLB, POLM | HSD11B1 2554/4885SLC6A4 2385/4885SLC1A2 1477/4885 |
| US-10130719-B2 | Compositions and methods relating to salts of specialized pro-resolving mediators | ALOX5, ALOX15, ALOX12 | HSD11B1 1028/4885SLC6A4 2999/4885SLC1A2 3340/4885 |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | ALOX15, ALOX12, PTGES | HSD11B1 123/4885SLC6A4 3135/4885SLC1A2 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.